针对急性髓性白血病的向治疗方法的概述
Sven Turkalj1,2, Felix A Radtke1,2,3, Paresh Vyas1,2,4
1MRC Molecular Hematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, United Kingdom.
HemaSphere
|June 12, 2023
概括
针对性疗法对急性髓性白血病 (AML) 有希望,但治疗耐药性和复发仍然是重大挑战. 创新的组合疗法对于改善这种侵袭性白血病的结果至关重要.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 急性髓性白血病 (AML) 是一种具有攻击性的血液癌症,其特征是血液细胞分化受损.
- 尽管取得了进展,但许多患者的预后不好,由于耐疗克隆,患者经常复发.
- 有针对性的疗法已经获得批准,但新的策略是必不可少的.
研究的目的:
- 审查目前针对AML的向治疗方法,包括已批准和正在研究的治疗方法.
- 突出AML中的分子漏洞,可以针对治疗.
- 讨论AML治疗策略的挑战和未来方向.
主要方法:
- 对针对性AML治疗的临床前研究和临床试验的审查.
- 对AML病原和治疗点的分子驱动因素的分析.
- 检查耐药机制及其对治疗的影响.
主要成果:
- 针对AML的几种向疗法已获得批准或正在开发中.
- 遗传突变,染色体异常和表观遗传变化是AML的关键驱动因素和目标.
- 特定于白血病干细胞的点提供了潜在的治疗效益.
结论:
- 针对性疗法代表了AML治疗的重大进展.
- 克服治疗耐药性和预防复发是关键的未满足需求.
- 针对分子脆弱性的合理组合疗法是AML治疗最有前途的未来方向.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Targets for Drug Action: Overview
6.5K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.5K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Therapies
7.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.8K


